Cargando…

Recent Developments in Combination Chemotherapy for Colorectal and Breast Cancers with Topoisomerase Inhibitors

DNA topoisomerases are important enzymes that stabilize DNA supercoiling and resolve entanglements. There are two main types of topoisomerases in all cells: type I, which causes single-stranded DNA breaks, and type II, which cuts double-stranded DNA. Topoisomerase activity is particularly increased...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jang, Jung Yoon, Kim, Donghwan, Kim, Nam Deuk
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10178955/ https://www.ncbi.nlm.nih.gov/pubmed/37176164 http://dx.doi.org/10.3390/ijms24098457

Ejemplares similares

Recent developments in topoisomerase-targeted cancer chemotherapy
por: Hevener, KirkE., et al.
Publicado: (2018)

Pathogenesis, Intervention, and Current Status of Drug Development for Sarcopenia: A Review
por: Jang, Jung Yoon, et al.
Publicado: (2023)

Topoisomerases and cancer chemotherapy: recent advances and unanswered questions
por: Bjornsti, Mary-Ann, et al.
Publicado: (2019)

MHY440, a Novel Topoisomerase Ι Inhibitor, Induces Cell Cycle Arrest and Apoptosis via a ROS-Dependent DNA Damage Signaling Pathway in AGS Human Gastric Cancer Cells
por: Jang, Jung Yoon, et al.
Publicado: (2018)

Therapeutic Potential of Bioactive Components from Scutellaria baicalensis Georgi in Inflammatory Bowel Disease and Colorectal Cancer: A Review
por: Jang, Jung Yoon, et al.
Publicado: (2023)

Developments in Non-Intercalating Bacterial Topoisomerase Inhibitors: Allosteric and ATPase Inhibitors of DNA Gyrase and Topoisomerase IV
por: Grossman, Scott, et al.
Publicado: (2023)

DNA topoisomerase IIα expression and the response toprimary chemotherapy in breast cancer
por: MacGrogan, G, et al.
Publicado: (2003)

Therapy-related acute leukemia in breast cancer patients: twelve cases treated with a topoisomerase inhibitor
por: Shim, Hyoeun, et al.
Publicado: (2010)

Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cancer cell lines.
por: Houlbrook, S., et al.
Publicado: (1995)

Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cancer cell lines
Publicado: (1996)

Metnase Mediates Resistance to Topoisomerase II Inhibitors in Breast Cancer Cells
por: Wray, Justin, et al.
Publicado: (2009)

Prognostic effect of class III β-tubulin and Topoisomerase-II in patients with advanced thymic carcinoma who received combination chemotherapy, including taxanes or topoisomerase-II inhibitors
por: Miura, Yosuke, et al.
Publicado: (2017)

Evaluating the recent developments in palliative chemotherapy for metastatic colorectal cancer
por: Baek, Sun Kyung, et al.
Publicado: (2019)

MHY2245, a Sirtuin Inhibitor, Induces Cell Cycle Arrest and Apoptosis in HCT116 Human Colorectal Cancer Cells
por: Kang, Yong Jung, et al.
Publicado: (2022)

MHY2251, a New SIRT1 Inhibitor, Induces Apoptosis via JNK/p53 Pathway in HCT116 Human Colorectal Cancer Cells
por: Kang, Yong Jung, et al.
Publicado: (2023)

Mechanism of Resveratrol-Induced Programmed Cell Death and New Drug Discovery against Cancer: A Review
por: Jang, Jung Yoon, et al.
Publicado: (2022)

Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer.
por: JÃ¤rvinen, T. A., et al.
Publicado: (1998)

Novel SIRT Inhibitor, MHY2256, Induces Cell Cycle Arrest, Apoptosis, and Autophagic Cell Death in HCT116 Human Colorectal Cancer Cells
por: Kim, Min Jeong, et al.
Publicado: (2020)

Targeting DNA Topoisomerase II in Antifungal Chemotherapy
por: Kondaka, Kavya, et al.
Publicado: (2022)

Encapsulation and Enhanced Delivery of Topoisomerase I Inhibitors in Functionalized Carbon Nanotubes
por: Chae, Sieun, et al.
Publicado: (2018)

Modification of topoisomerases in mammospheres derived from breast cancer cell line: clinical implications for combined treatments with tyrosine kinase inhibitors
por: Peleg, Refael, et al.
Publicado: (2014)

Topoisomerase 2 alpha as a predictor of response to anthracycline neoadjuvant chemotherapy in locally advanced breast cancer
por: Shehata, M, et al.
Publicado: (2010)

PROGNOSTIC VALUE OF TOPOISOMERASE 2-ALPHA AND B-MYB IN EARLY BREAST CANCER TREATED WITH ADJUVANT CHEMOTHERAPY
por: Radmilović Varga, Ljubica, et al.
Publicado: (2021)

The Structural Features of Novel Bacterial Topoisomerase Inhibitors That Define Their Activity on Topoisomerase IV
por: Kokot, Maja, et al.
Publicado: (2022)

Activity of M3814, an Oral DNA-PK Inhibitor, In Combination with Topoisomerase II Inhibitors in Ovarian Cancer Models
por: Wise, Hannah C., et al.
Publicado: (2019)

Prospects of Topoisomerase Inhibitors as Promising Anti-Cancer Agents
por: Yakkala, Prasanna Anjaneyulu, et al.
Publicado: (2023)

Chemotherapy-Associated Hepatopathy in Korean Colorectal Cancer Liver Metastasis Patients: Oxaliplatin-Based Chemotherapy and Sinusoidal Injury
por: Nam, Soo Jeong, et al.
Publicado: (2012)

Topoisomerase I inhibition in colorectal cancer: biomarkers and therapeutic targets
por: Gilbert, D C, et al.
Publicado: (2012)

Hyperthermia, thermotolerance and topoisomerase II inhibitors.
por: Kampinga, H. H.
Publicado: (1995)

High Antitumor Activity of the Dual Topoisomerase Inhibitor P8-D6 in Breast Cancer
por: Flörkemeier, Inken, et al.
Publicado: (2021)

Carvacrol-Fabricated Chitosan Nanoparticle Synergistic Potential with Topoisomerase Inhibitors on Breast and Cervical Cancer Cells
por: Akhlaq, Amina, et al.
Publicado: (2023)

Role of Induced Programmed Cell Death in the Chemopreventive Potential of Apigenin
por: Jang, Jung Yoon, et al.
Publicado: (2022)

Mechanism of Bile Acid-Induced Programmed Cell Death and Drug Discovery against Cancer: A Review
por: Jang, Jung Yoon, et al.
Publicado: (2022)

Molecular subtypes of breast cancer and amplification of topoisomerase IIα: predictive role in dose intensive adjuvant chemotherapy
por: Hannemann, J, et al.
Publicado: (2006)

Long-lasting reduction in clonogenic potential of colorectal cancer cells by sequential treatments with 5-azanucleosides and topoisomerase inhibitors
por: Pawlak, Alicja, et al.
Publicado: (2016)

Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development.
por: Gerrits, C. J., et al.
Publicado: (1997)

Topoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy
por: Kostopoulos, Ioannis, et al.
Publicado: (2009)

Topoisomerase I and IIα protein expression in primary colorectal cancer and recurrences following 5-fluorouracil-based adjuvant chemotherapy
por: Tsavaris, Nicolas, et al.
Publicado: (2008)

Topoisomerase I and IIα protein expression in primary colorectal cancer and recurrences following 5-fluorouracil-based adjuvant chemotherapy
por: Tsavaris, Nicolas, et al.
Publicado: (2009)

Combination chemotherapy for advanced colorectal cancer
por: Mason, M, et al.
Publicado: (2003)

Cannot write session to /tmp/vufind_sessions/sess_m0sdj4olkj4k9iherhqnmkv5ha